OZOBAX DS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ozobax Ds, and what generic alternatives are available?
Ozobax Ds is a drug marketed by Metacel Pharms Llc and is included in one NDA.
The generic ingredient in OZOBAX DS is baclofen. There is one drug master file entry for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ozobax Ds
A generic version of OZOBAX DS was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OZOBAX DS?
- What are the global sales for OZOBAX DS?
- What is Average Wholesale Price for OZOBAX DS?
Summary for OZOBAX DS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Patent Applications: | 4,977 |
| DailyMed Link: | OZOBAX DS at DailyMed |
Pharmacology for OZOBAX DS
| Drug Class | gamma-Aminobutyric Acid-ergic Agonist |
| Mechanism of Action | GABA A Agonists GABA B Agonists |
US Patents and Regulatory Information for OZOBAX DS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metacel Pharms Llc | OZOBAX DS | baclofen | SOLUTION;ORAL | 208193-002 | Oct 12, 2023 | AA | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
